NEW
Stock Screener with Intrinsic Value
Royalty Pharma plc (RPRX)
Last Price$30.8(0.6%)
Market Cap$13.8B
Relative value
$52.4
Undervalued (Relative Value)
70.4%
NTM P/E
4.6x
Peer set median: 11.2x
1Y Fwd EV/EBITDA
9.1x
Peer set median: 10.5x
Stock quality
7/10
Good
RPRX Relative Value & Intrinsic Value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
RPRX Valuation Multiples comparison vs Peer Set
Crunching data... Almost there!
RPRX Valuation multiples overview
Crunching data... Almost there!
RPRX Valuation multiples history vs. Peer set
Crunching data... Almost there!
Explore more intrinsic value tools hub for RPRX
DCF value calculator
Peter Lynch Fair Value
Earnings Power Value
Intrinsic Value
Reverse DCF
Margin of safety
Peter Lynch charts
Earnings growth model
Ben Graham Fair Value
Discount rate
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Royalty Pharma plc relative value?
As of Jan 17, 2025, Apple Relative Value is $52.4. This suggests it may be overvalued by 70.4% compared to its current price of around $30.8.
What is Royalty Pharma plc DCF (discounted cash flow) valuation?
As of Jan 17, 2025, Royalty Pharma plc's Discounted Cash Flow (DCF) valuation estimates its share price at $356.6. This suggests it may be overvalued by 1,059.6% to its current price of around $30.8, using a discount rate of 5.4% and terminal growth rate of 3.0%.
What is Royalty Pharma plc intrinsic value?
As of Jan 17, 2025, Apple Intrinsic Value is $204.5. This suggests it may be undervalued by 565.0% compared to its current price of around $30.8.